India, a home of the largest pediatric population of the world
and also has the highest number of annual child births in the world. However,
almost 80-90% of the drugs used in children presently have never been studied
for their efficacy in pediatric population. In India, results of the studies
conducted in adult population are extrapolated for use in children. There are
no specific medicine development regulations for pediatrics. Indian clinical
practice relies heavily upon safety and efficacy data published in other
developed countries or on inference from adult dosing.
India
pediatric drugs and vaccine market has witnessed tremendous growth in the
last five years largely due to high number of annual births recorded at around
~ million, launch of generic formulations of several pediatric drugs including flavored
TB drugs, inclusion of several vaccines against diseases by virtue of few doses
of vaccines. On the other hand, repeated incidence of some or the other
non-vaccine preventable medical conditions coupled with comparatively heavy
requirement of drug doses have resulted in a far greater usage of drugs.
How Has The Pediatric Drugs Segment Performed?
Indian
pediatric drug industry has been driven by the overwhelming performance of the
pharmaceutical industry which is the third largest pharmaceutical market in
terms of volume and thirteenth largest in terms of value, contributing towards
10% of global production.
The
pediatric drugs market in India grew at a staggering CAGR of ~% during the
period FY’2011-FY’2016 from INR ~ billion in FY’2011 to INR ~ billion in
FY’2016. Owing to an astounding number of births in the country, the pediatric
drugs market exhibited growth at a faster pace than the overall pharmaceutical
market of the country during the concerned period. Rising prevalence in the
diseases among children is other major factor which has led to the growth in
the market during the historical period. For instance, Asthma has been observed
to grow at a rapid pace during the historical period. In fact, the market grew
by over ~% in FY’2016 due to the launch of flavored TB drugs and WHO’s alliance
with Mumbai based Macleods Pharmaceuticals to developed TB drugs for children
and supply it globally.
How has the Pediatric Drugs Segment Performed?
About
~% of child mortality is registered in the country. Respiratory diseases
including pneumonia and tuberculosis are other commonly treatable conditions
for which drugs find extensive usage in the country. Nearly ~ million children
are reported to die due to pneumonia every year.
Owing
to less prevalence of lifestyle diseases amongst pediatric population, market
share of drugs meant for management of diseases has been low. Drug meant for
management of diseases are typically chronic diseases, particularly
degenerative non-communicable diseases (NCDs) such as chronic respiratory
diseases, cardiovascular diseases, cancer, HIV/AIDS and diabetes amongst
others.
For more
information about the publication, refer to below link:
Related Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
